130 related articles for article (PubMed ID: 14964003)
1. [Acute respiratory tract infection in chronically ill patients. germ spectrum different than in healthy persons].
MMW Fortschr Med; 2003 Dec; 145(49):61. PubMed ID: 14964003
[No Abstract] [Full Text] [Related]
2. [Importance in respiratory tract infections. Ketolides: clinical aspects].
Lorenz J; Steiert P
Pharm Unserer Zeit; 2004; 33(1):42-6. PubMed ID: 14968712
[No Abstract] [Full Text] [Related]
3. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
Reinert RR
J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
[TBL] [Abstract][Full Text] [Related]
4. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
5. [Resistance of respiratory tract infection agents is still increasing. Is its time for new antibiotic strategies?].
MMW Fortschr Med; 2003 Feb; 145(9):55. PubMed ID: 12666535
[No Abstract] [Full Text] [Related]
6. [Evaluation of ketoride antibiotics, telithromycin in treatment of respiratory tract infections (discussion)].
Kohno S; Watanabe A; Aoki N; Niki Y
Jpn J Antibiot; 2003 Dec; 56(6):531-45. PubMed ID: 15007871
[No Abstract] [Full Text] [Related]
7. Telithromycin (Ketek) for respiratory infections.
Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
[No Abstract] [Full Text] [Related]
8. [Telithromycin: a new therapeutic option for community-acquired respiratory infection].
Muñoz MJ; Azanza JR; Escolar M; Macaya A; Gil FJ
Rev Med Univ Navarra; 2002; 46(3):37-44. PubMed ID: 12685116
[No Abstract] [Full Text] [Related]
9. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
10. Telithromycin (Ketek) for community-acquired respiratory tract infections.
Wimett L; Laustsen G
Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
[No Abstract] [Full Text] [Related]
11. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
12. [A new antibiotic against respiratory tract infections. More power against pneumococci].
MMW Fortschr Med; 2001 Nov; 143(44):59. PubMed ID: 11732406
[No Abstract] [Full Text] [Related]
13. [Efficacy trial in general practice substantiated. New antibiotic with strong effectiveness and tolerance].
MMW Fortschr Med; 2002 Oct; 144(42):60-1. PubMed ID: 12534000
[No Abstract] [Full Text] [Related]
14. Long-term macrolide treatment for chronic respiratory disease.
Spagnolo P; Fabbri LM; Bush A
Eur Respir J; 2013 Jul; 42(1):239-51. PubMed ID: 23180583
[TBL] [Abstract][Full Text] [Related]
15. [Telithromycin in the management of lower respiratory tract infections in the hospital].
Léophonte P
Presse Med; 2003 Jun; 32(20):952-3. PubMed ID: 12876542
[No Abstract] [Full Text] [Related]
16. New treatment options for lower respiratory tract infections.
Kocsis B; Szabo D
Expert Opin Pharmacother; 2017 Sep; 18(13):1345-1355. PubMed ID: 28762839
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
18. [Bacterial airway infections. Standard antibiotics more often ineffective].
MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910829
[No Abstract] [Full Text] [Related]
19. Macrolides in dermatology.
Scheinfeld NS; Tutrone WD; Torres O; Weinberg JM
Dis Mon; 2004 Jul; 50(7):350-68. PubMed ID: 15280867
[No Abstract] [Full Text] [Related]
20. Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections.
Nord CE; Farrell DJ; Leclercq R
Microb Drug Resist; 2004; 10(3):255-63. PubMed ID: 15383171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
